Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERGOMAR vs METHERGINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ergotamine acts as a partial agonist at serotonin 5-HT1B and 5-HT1D receptors, causing vasoconstriction of cranial blood vessels. It also inhibits norepinephrine reuptake and has alpha-adrenergic blocking activity.
Methylergonovine is an ergot alkaloid that acts as a partial agonist at α-adrenergic receptors in the uterine smooth muscle, causing sustained contractions. It also exhibits serotonergic (5-HT2) and dopaminergic activity.
Abortive treatment of acute migraine headaches with or without aura,Cluster headache
Prevention and treatment of postpartum hemorrhage due to uterine atony,Management of incomplete abortion
Ergotamine tartrate 1-2 mg sublingually or orally at onset of migraine, then 1-2 mg every 30 minutes as needed, maximum 6 mg per attack and 10 mg per week.
0.2 mg intramuscularly or intravenously after delivery of placenta and every 2-4 hours as needed, up to a maximum of 5 doses.
Terminal elimination half-life is approximately 2-3 hours for ergotamine, but clinical effects may persist longer due to active metabolites (e.g., ergotamine's half-life is 2.4 hours; metabolites have half-lives up to 10 hours).
Terminal elimination half-life is approximately 2–3 hours in healthy adults; prolonged in hepatic impairment.
Primarily hepatic via CYP3A4; minor contributions from CYP2D6. Undergoes extensive first-pass metabolism.
Primarily hepatic via CYP3A4 with significant first-pass metabolism; active metabolite is methylergonovine itself; excreted mainly in bile and urine.
Primarily hepatic metabolism with extensive biliary excretion; less than 5% excreted unchanged in urine. Fecal elimination accounts for approximately 30-40% of the dose as metabolites.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Biliary/fecal excretion accounts for ~80% of metabolites.
90-95% bound to plasma proteins, primarily albumin.
Approximately 93% bound, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 0.4 L/kg (16-18 L in adults), indicating moderate tissue distribution.
0.6 L/kg (range 0.3–0.8 L/kg), indicating moderate distribution into tissues.
Sublingual: ~40-50%; Oral: <10% due to extensive first-pass metabolism; Rectal: ~25-30%.
Oral bioavailability is approximately 10–20% due to extensive first-pass metabolism. Intramuscular administration provides 100% bioavailability.
GFR > 30 m L/min: No adjustment. GFR 10-30 m L/min: Caution; reduce dose by 50%. GFR < 10 m L/min: Contraindicated.
No specific dose adjustment recommended; use with caution in renal impairment due to risk of hypertension.
Child-Pugh A: Caution; reduce dose by 50%. Child-Pugh B: Contraindicated. Child-Pugh C: Contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For Child-Pugh class A or B, use with caution and monitor for signs of toxicity.
Not recommended for children under 12 years. Pediatric use not established; avoid use.
Not recommended for pediatric use; safety and efficacy in children have not been established.
Elderly patients are more sensitive to vasoconstriction; use lower initial dose (e.g., 1 mg) and monitor for adverse effects.
Use with caution in elderly patients due to increased sensitivity to vasoconstrictive effects and higher risk of hypertension and myocardial ischemia.
Serious and/or life-threatening peripheral ischemia and vasospasm have been associated with the concomitant use of ergotamine with potent CYP3A4 inhibitors including protease inhibitors, macrolide antibiotics, and azole antifungals.
Not for use during pregnancy (except during delivery) due to risk of uterine tetany and fetal hypoxia. Contraindicated in patients with hypertension, preeclampsia, or eclampsia due to risk of severe hypertension and stroke.
Risk of ischemic events (peripheral, cardiac, cerebral), fibrosis (retroperitoneal, pulmonary, cardiac), elderly patients (more sensitive to adverse effects), ergotism, drug interactions with CYP3A4 inhibitors, and prolonged use leading to medication-overuse headache.
Risk of severe hypertension, especially in patients with preeclampsia, eclampsia, or hypertension.,Use with caution in patients with sepsis, hepatic or renal impairment, or coronary artery disease.,May cause ergotism with prolonged use or high doses (symptoms: vasospasm, ischemia).,Monitor blood pressure and uterine response during administration.
Hypersensitivity to ergot alkaloids, peripheral vascular disease, coronary artery disease, uncontrolled hypertension, sepsis, hepatic or renal impairment, pregnancy, breastfeeding, concomitant use with potent CYP3A4 inhibitors, hemiplegic or basilar migraine.
Hypersensitivity to ergot alkaloids,Pregnancy (for antepartum use),Hypertension, preeclampsia, or eclampsia,Peripheral vascular disease,Coronary artery disease,Severe hepatic or renal impairment,Sepsis
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, increasing ergotamine levels and risk of toxicity. No other significant food interactions.
Avoid grapefruit juice as it may increase serum levels of methylergonovine via CYP3A4 inhibition. No specific food restrictions other than avoiding excessive caffeine intake, which may potentiate vasoconstrictive effects.
Ergotamine (ERGOMAR) is contraindicated in pregnancy due to its oxytocic properties and potential for uterine hyperstimulation, fetal hypoxia, and congenital anomalies. First trimester: Increased risk of spontaneous abortion and major malformations (e.g., limb defects, CNS abnormalities) based on case reports. Second and third trimesters: Uterine hypertonicity and decreased placental perfusion leading to fetal distress, preterm labor, and low birth weight. Use only if benefit outweighs risk and no alternative; avoid in all trimesters.
Methergine (methylergonovine) is contraindicated in pregnancy due to its oxytocic properties and risk of uterine hyperstimulation, fetal distress, and abortion. First trimester: potential teratogenic effects not well studied; avoid use. Second and third trimesters: can cause abruptio placentae, premature labor, and fetal anoxia. It is FDA Pregnancy Category X.
Ergotamine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.5-0.9. Potential for ergotism symptoms in infants (vomiting, diarrhea, seizures). It may also reduce milk production due to prolactin inhibition. Contraindicated during breastfeeding per manufacturer guidelines. If exposure occurs, monitor infant for symptoms and consider abrupt cessation.
Methylergonovine is excreted into breast milk in small amounts; the milk-to-plasma ratio is approximately 1.0. Adverse effects in nursing infants are rare but may include diarrhea, vomiting, and hypertension. It is generally considered compatible with breastfeeding when used short-term for postpartum hemorrhage. Avoid prolonged use.
Pregnancy may alter ergotamine pharmacokinetics (increased plasma volume, renal clearance, hepatic metabolism), but no established dose adjustment guidelines. Standard doses may be ineffective or toxic due to variable absorption. Avoid use if possible; if necessary, lowest effective dose for shortest duration, with close monitoring for toxicity.
Not applicable; the drug is contraindicated during pregnancy. No dose adjustments are recommended for use during pregnancy as it should not be used.
Ergomar (ergotamine tartrate sublingual tablets) is a first-line abortive therapy for acute migraine attacks, but its use is limited by vasoconstrictive risks. Avoid in patients with coronary artery disease, hypertension, peripheral vascular disease, or pregnancy. Administer at the first sign of migraine; sublingual route offers rapid absorption. Concomitant use with potent CYP3A4 inhibitors (e.g., macrolides, protease inhibitors) is contraindicated due to risk of ergotism. Limit total dose to 6 mg per attack and 10 mg per week.
METHERGINE (methylergonovine) is an ergot alkaloid used primarily for postpartum hemorrhage due to uterine atony. Do not use for routine induction of labor or for threatened abortion. Avoid in patients with hypertension, preeclampsia, coronary artery disease, or severe hepatic/renal disease. Monitor blood pressure closely during administration. Administer intramuscularly for rapid effect; onset is 2-5 minutes. Intravenous administration should be reserved for emergencies due to risk of hypertensive crisis. Contraindicated in pregnancy except immediately after delivery. Drug interactions: avoid concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, macrolides, protease inhibitors) due to risk of ergotism and vasospasm. As of April 2025, there is no generic form; brand METHERGINE only.
Take one sublingual tablet at the first sign of migraine, placing it under the tongue to dissolve, and do not swallow.,Do not exceed 3 tablets per attack or 5 tablets per week; overuse can lead to serious side effects.,Seek immediate medical attention if you experience symptoms of ergotism like severe coldness, numbness, or pain in hands/feet, muscle cramps, chest pain, or rapid heartbeat.,Avoid grapefruit and grapefruit juice during treatment as it may increase the risk of side effects.,Inform your doctor if you are pregnant, breastfeeding, or have any history of heart disease, high blood pressure, or peripheral artery disease.
This medication is used to prevent or treat excessive bleeding after childbirth by causing contractions of the uterus.,Report immediately if you experience severe headache, chest pain, vision changes, muscle cramps, or numbness/tingling in the arms or legs.,Avoid breastfeeding within 8 hours after the last dose if possible; if breastfeeding is necessary, pump and discard for 8 hours to reduce infant exposure.,Do not use this medication if you have uncontrolled high blood pressure, heart disease, or liver/kidney disease.,Avoid alcohol and grapefruit juice while on this medication as they may affect blood levels.,Take this medication exactly as prescribed; do not take double doses if a dose is missed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERGOMAR vs METHERGINE, answered by our medical review team.
ERGOMAR is a Ergot Alkaloid Antimigraine that works by Ergotamine acts as a partial agonist at serotonin 5-HT1B and 5-HT1D receptors, causing vasoconstriction of cranial blood vessels. It also inhibits norepinephrine reuptake and has alpha-adrenergic blocking activity.. METHERGINE is a Ergot Alkaloid Uterotonic that works by Methylergonovine is an ergot alkaloid that acts as a partial agonist at α-adrenergic receptors in the uterine smooth muscle, causing sustained contractions. It also exhibits serotonergic (5-HT2) and dopaminergic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERGOMAR and METHERGINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERGOMAR is: Ergotamine tartrate 1-2 mg sublingually or orally at onset of migraine, then 1-2 mg every 30 minutes as needed, maximum 6 mg per attack and 10 mg per week.. The standard adult dose of METHERGINE is: 0.2 mg intramuscularly or intravenously after delivery of placenta and every 2-4 hours as needed, up to a maximum of 5 doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERGOMAR and METHERGINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERGOMAR is classified as Category C. Ergotamine (ERGOMAR) is contraindicated in pregnancy due to its oxytocic properties and potential for uterine hyperstimulation, fetal hypoxia, and congenital anomalies. First trime. METHERGINE is classified as Category C. Methergine (methylergonovine) is contraindicated in pregnancy due to its oxytocic properties and risk of uterine hyperstimulation, fetal distress, and abortion. First trimester: po. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.